Stelo Sensor: How It Works, Accuracy, and When to Use It

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult your physician or a qualified healthcare provider regarding any medical condition or treatment.

Key Takeaways

  • The Stelo sensor is a 15-day over-the-counter CGM from Dexcom, cleared by the FDA in March 2024.
  • It is designed for adults 18+ who are not on insulin, including people with prediabetes or type 2 diabetes.
  • Stelo reads glucose every 15 minutes and shows data in the Stelo app; it does not include urgent-low alarms.
  • Discuss results with your doctor; Stelo is a lifestyle tool, not a medical monitor for hypoglycemia management.

The Stelo sensor is the first FDA-cleared over-the-counter continuous glucose monitor in the United States, launched by Dexcom in March 2024. Designed for adults 18 and older who are not on insulin, Stelo lets people with prediabetes, type 2 diabetes managed without insulin, or general metabolic-health curiosity track glucose without a prescription.

How the Stelo Sensor Works

Stelo uses the same subcutaneous sensing technology as Dexcom’s prescription G7 CGM. A tiny filament sits in interstitial fluid, where glucose reacts with an enzyme to generate a measurable current. That current is translated into a glucose value by the transmitter and sent to your smartphone every 15 minutes via Bluetooth.

The sensor sits on the back of the upper arm, is waterproof, and lasts 15 days, longer than the prescription G7’s 10-day wear.

Who Is Stelo For?

The FDA cleared Stelo for adults 18 and older who do not use insulin. This deliberately includes:

  • Adults with prediabetes wanting to see real-time responses to meals
  • People with type 2 diabetes managed with metformin, GLP-1s, or lifestyle alone
  • Health-focused adults interested in metabolic insights without a medical indication

It excludes type 1 diabetes, insulin users, pregnant women, and children. If you fall outside these groups, a prescription CGM is the appropriate choice. To understand how continuous data fits with traditional testing, see our A1C levels guide.

Stelo vs Dexcom G7 vs Abbott Lingo

Feature Stelo Dexcom G7 Abbott Lingo
Prescription No Yes No
Sensor life 15 days 10.5 days 14 days
Reading interval 15 min 5 min 1 min
Urgent low alert No Yes No
Starting price ~$49/sensor ~$125/sensor ~$49/sensor
Indication Non-insulin adults All diabetes types Wellness

Setting Up Stelo

Order directly from stelo.com or purchase at participating pharmacies. Download the Stelo app, pair the sensor, and apply it to the back of the upper arm using the pre-loaded applicator. The sensor warms up for 30 minutes before showing glucose data.

The app is intentionally simpler than Dexcom G7’s clinical interface. It highlights “Spike” events, meal windows, and 24-hour patterns rather than granular trend arrows. This framing matches the lifestyle use case the FDA reviewed.

Interpreting Stelo Data

Target ranges for non-diabetic adults are generally 70 to 140 mg/dL, with post-meal peaks rarely exceeding 140. People with prediabetes may see peaks of 140 to 180 mg/dL, especially after refined carbohydrates. The FDA clearance press release emphasizes that Stelo is a lifestyle tool, not a replacement for clinical assessment.

Use Stelo data to identify individual responses. Some people spike more on oatmeal than on a bagel because of personal metabolism, gut microbiome, and fitness. For dietary guidance that pairs well with CGM insights, see our diet and nutrition hub.

Limitations of Stelo

Stelo does not have urgent-low alarms, cannot be used for insulin dosing decisions, and reports at 15-minute intervals rather than five. The app also smooths short glucose spikes to avoid alarming users with normal physiological variability. These are intentional design choices, not flaws, but they mean Stelo is unsuitable for anyone at risk of hypoglycemia.

The sensor may also be less accurate in the first and last 24 hours of wear, a pattern common to all CGMs.

When to Talk to Your Doctor

Share your Stelo data with your clinician if you see:

  • Sustained glucose above 180 mg/dL after most meals
  • Fasting glucose consistently above 110 mg/dL
  • Any glucose readings below 70 mg/dL
  • Large variability (range greater than 60 mg/dL within a day)

These patterns warrant formal testing such as a fasting glucose, oral glucose tolerance test, or HbA1c.

The Bottom Line

The Stelo sensor brings medical-grade glucose tracking to adults without insulin therapy, at a fraction of prescription CGM cost. It is a powerful educational tool for people with prediabetes or early type 2 diabetes, but it is not a substitute for medical care. Use Stelo insights to refine lifestyle choices, and always involve your healthcare provider in treatment decisions.

This article is educational and not medical advice. Consult your healthcare provider before making medication or dietary changes based on CGM data.

Frequently Asked Questions

How much does the Stelo sensor cost?

Stelo retails at roughly $89 for a pack of two sensors (30 days of wear), or about $49 for a single 15-day sensor purchased direct from Dexcom. Subscription plans offer modest discounts. Prices may vary by retailer and region.

Is the Stelo sensor as accurate as Dexcom G7?

Stelo uses the same hardware platform as the Dexcom G7 and achieves comparable accuracy, with a Mean Absolute Relative Difference in single digits. However, Stelo updates every 15 minutes rather than every five, and the app deliberately smooths short-term spikes to avoid alarming non-diabetic users.

Can you wear a Stelo sensor if you are on insulin?

Stelo is not cleared for people who use insulin. The FDA specifically limited its indication to adults 18 and older not on insulin therapy. If you use insulin, you need a prescription CGM like Dexcom G7 or Freestyle Libre 3 that includes urgent-low alerts and insulin-dosing accuracy labeling.

How long does a Stelo sensor last?

Each Stelo sensor lasts 15 days, which is 50% longer than the prescription Dexcom G7. The extended wear is possible because Stelo's indication for non-insulin users has less stringent late-life accuracy requirements than insulin-dosing CGMs.

Sources

  1. FDA news release — First OTC continuous glucose monitor, March 2024
  2. Dexcom Stelo product information and user guide
  3. ADA Standards of Care 2024 — Section 7, Diabetes Technology
  4. Consumer Reports CGM review, 2024